SCHEMBL3445900

SCHEMBL3445900

COC(=O)C(C)(C)c1ccc(N)c(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.48
CNR2 P34972 1/20 0.48
AKR1C3 P42330 2/20 0.43
AKR1C2 P52895 2/20 0.43
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
CFTR P13569 1/20 0.42
APP P05067 1/20 0.39
ALDH1A1 P00352 2/20 0.37
POLB P06746 1/20 0.37
KCNN4 O15554 1/20 0.36
HDAC3 O15379 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
BRS3 P32247 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6188164 0.87 HDAC1 (0.42) CNR1CNR2AKR1C3AKR1C2HDAC1
SCHEMBL7472692 0.85 CNR1 (0.51) CNR1CNR2AKR1C3AKR1C2HDAC1
SCHEMBL14035562 0.83 CNR2 (0.45) CNR2AKR1C3AKR1C2HDAC1HDAC6
SCHEMBL30192734 0.83 CNR2 (0.45) CNR2AKR1C3AKR1C2HDAC1HDAC6
SCHEMBL23582257 0.82 CNR2 (0.60) CNR1CNR2CFTRALDH1A1POLB
SCHEMBL31357589 0.82 CNR2 (0.60) CNR1CNR2CFTRALDH1A1POLB
SCHEMBL24195985 0.81 APP (0.56) AKR1C3AKR1C2HDAC1HDAC6APP
SCHEMBL9612065 0.81 CNR1 (0.48) CNR1CNR2CFTRALDH1A1POLB
SCHEMBL25168297 0.81 CNR2 (0.48) CNR1CNR2AKR1C3AKR1C2CFTR
SCHEMBL1626715 0.81 CNR1 (0.48) CNR1CNR2AKR1C3AKR1C2APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103958472-A Aryl-or N-heteroaryl-substituted methanesulfonamide derivatives as vanilloid receptor ligands GRUENENTHAL GMBH 2014-07-30 CN disclosed
US-7816540-B2 Carboxyl- or hydroxyl-substituted benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-10-19 US disclosed
EP-2225221-A2 CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-08 EP disclosed
WO-2009080555-A2 CARBOXYL- OR HYDROXYL- SUBSTITUTED BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-07-02 WO disclosed
US-20090163552-A1 CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163552-A1 CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES NR1H4, GPBAR1, SLC10A1 CNR1 189/4885CNR2 327/4885AKR1C3 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.